A leading pharmaceutical company required an eCOA vendor to support a group of oncology studies in multiple oncology indications. The eCOA solution needed to be customized for each study to enable sites to easily enroll the right patients, capture site-based Quality of Life (QoL) assessments on tablets and deliver engaging training content.
This study program involved 200 sites across 30 countries with approximately 2,500 patients across several indications, including:
- Solid tumors
- Prostate cancer
- Hodgkin’s Lymphoma
- Bladder cancer
- Lung Cancer
QoL assessments were collected from patients at each investigative site, including EQ-5D, QLQ-C30 and FACT-P.
ERT’s eCOA solution provided efficient deployment of eCOA assessments across oncology studies in various indications.
A range of QoL assessments were delivered on user-friendly tablets, along with:
- Integrated, secure online enrollment of patients
- Animated, engaging patient training content
- Accurate, real-time reporting
Since assessments were to be collected during site visits, the solution was deployed on provisioned tablet devices to provide a simple interface for patients and ensure high-quality, electronic data capture.
The ERT eCOA solution supported patient data capture at each site across multiple studies, achieving the pharma’s program goals. The use of site-based animated training material ensured that the solution was easily understood by users. The solution also streamlined the online patient enrollment process.
In addition to cost-effectively integrating eCOA assessments, ERT provided real-time access to study data and reporting, enabling faster decision making while helping the sponsor to develop a library of validated QoL assessments.
Accelerate your research with eCOA solutions that engage sites and patients. To learn more, go to ert.com or email [email protected]